Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

NCT03624036 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

16

Enrollment

INDUSTRY

Sponsor class

Stopped Development program terminated

Conditions

Relapsed/Refractory Chronic Lymphocytic Leukemia and Relapsed/Refractory Small Lymphocytic Lymphoma

Interventions

BIOLOGICAL: brexucabtagene autoleucel
DRUG: Fludarabine
DRUG: Cyclophosphamide

Sponsor

Kite, A Gilead Company